Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.50 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.50 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31706768 | 1.00 | KMO (0.60) | KMOPOLBPLOD2PLOD3PLOD1 | |
| SCHEMBL20187819 | 0.88 | CHRNB2 (0.51) | KMOPOLBALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL29420013 | 0.88 | CHRNB2 (0.51) | KMOPOLBALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL7675542 | 0.86 | PLOD2 (0.49) | KMOPOLBPLOD2PLOD3PLOD1 | |
| SCHEMBL5593185 | 0.85 | ALDH1A1 (0.57) | KMOPOLBL3MBTL1ALDH1A1SMN1; SMN2 | |
| Lithium Ion SCHEMBL31705607 | 0.84 | PLOD2 (0.48) | KMOPOLBPLOD2PLOD3PLOD1 | |
| SCHEMBL23610380 | 0.83 | CHRNB2 (0.55) | KMOPOLBALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL29420017 | 0.83 | CHRNB2 (0.55) | KMOPOLBALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL3941724 | 0.83 | KDM4E (0.56) | POLBL3MBTL1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL664858 | 0.82 | ATM (0.50) | KMOPLOD2PLOD3PLOD1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| EP-3856179-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-08-04 | — | — | EP | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2396307-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093419-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007075896-A2 | HETEROCYCLIC CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMO 615/4885POLB 2574/4885PLOD2 3666/4885 |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | KMO 3377/4885POLB 2028/4885PLOD2 4703/4885 |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | KMO 3271/4885POLB 479/4885PLOD2 4274/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KMO 615/4885POLB 2574/4885PLOD2 3666/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | KMO 904/4885POLB 4291/4885PLOD2 3839/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMO 615/4885POLB 2574/4885PLOD2 3666/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KMO 615/4885POLB 2574/4885PLOD2 3666/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMO 615/4885POLB 2574/4885PLOD2 3666/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMO 615/4885POLB 2574/4885PLOD2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.